ClinicalTrials.Veeva

Menu

Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD

S

Sequenom

Status

Completed

Conditions

Choroidal Neovascularization
Age Related Macular Degeneration
Central Serous Chorioretinopathy

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT01880788
SCMM-AMD-107

Details and patient eligibility

About

The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis.

Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.

Full description

To determine if patients presenting with type 1 neovascularization believed to be secondary to CSC are genetically distinct from typical CSC patients without neovascularization or patients presenting with choroidal neovascularization (CNV) secondary to advanced AMD. Disease associated markers detecting variants in ARMS 2, Complement Factor H (CFH) Complement component 3 (C3), Complement component 2 (C2) , Factor B (FB), VEGFA or other genetic polymorphisms associated with CNV will be evaluated to determine if the CSC neovascular group is genetically distinct from the CSC group without neovascularization or the advanced AMD group.

Enrollment

152 patients

Sex

All

Ages

30+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Caucasian
  • 30 years and older (CSC)
  • 50 years and older (Advanced AMD)
  • Genders Eligible for Study: Both
  • Completed Consent form
  • Diagnosis of choroidal neovascularization in at least one eye

Exclusion criteria

  • Patient age less than 30 years (CSC).
  • Patient age less than 50 years (AMD).
  • Presence of retinal disease involving the photoreceptors and/or outer retinal layers other than AMD and CSC such as high myopia, retinal dystrophies, retinal vein occlusion, diabetic retinopathy and uveitis or similar outer retinal diseases which have been present prior to the age of 30.
  • Opacities of the ocular media, limitations of pupillary dilation or other problems sufficient to preclude adequate fundus photography.
  • Missing informed consent
  • Previous sample donation under this protocol

Trial design

152 participants in 3 patient groups

CNV secondary to CSC
CSC without CNV
CNV secondary to advanced AMD

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems